

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:
22-264

MEDICAL REVIEW(S)

CLINICAL REVIEW

Application Type NDA
Application Number(s) 22264-000
Priority or Standard S (Resubmission)

Submit Date(s) 03 February 2009
Received Date(s) 04 February 2009
PDUFA Goal Date 03 August 2009
Division / Office DPP/ONE1

Reviewer Name(s) Jing Zhang, MD, PhD
Review Completion Date June 8, 2009

Established Name Paliperidone Palmitate
(Proposed) Trade Name Invega[®] Sustenna[™]
Therapeutic Class Atypical Antipsychotic
Applicant Johnson & Johnson

Formulation(s) Long-Acting Injection
Dosing Regimen Injection Every 4 Weeks
Indication(s) Acute Treatment of
Schizophrenia
Intended Population(s) Adults

Template Version: [March 6, 2009](#)

Table of Contents

1	RECOMMENDATIONS/RISK BENEFIT ASSESSMENT	7
1.1	Recommendation on Regulatory Action	7
1.2	Risk Benefit Assessment.....	7
1.3	Recommendations for Postmarket Risk Evaluation and Mitigation Strategies ...	8
1.4	Recommendations for Postmarket Requirements and Commitments	8
2	INTRODUCTION AND REGULATORY BACKGROUND	9
2.1	Product Information	9
2.2	Product Tables of Currently Available Treatments for Proposed Indication.....	9
2.3	Availability of Proposed Active Ingredient in the United States	10
2.4	Important Safety Issues with Consideration to Related Drugs.....	10
2.5	Summary of Presubmission Regulatory Activity Related to Submission	10
2.6	Other Relevant Background Information	11
3	ETHICS AND GOOD CLINICAL PRACTICES.....	11
3.1	Submission Quality and Integrity	11
3.2	Compliance with Good Clinical Practices	11
3.3	Financial Disclosures.....	11
4	SIGNIFICANT EFFICACY/SAFETY ISSUES RELATED TO OTHER REVIEW DISCIPLINES	12
4.1	Chemistry Manufacturing and Controls	12
4.2	Clinical Microbiology	12
4.3	Preclinical Pharmacology/Toxicology	12
4.4	Clinical Pharmacology	12
4.4.1	Mechanism of Action.....	12
4.4.2	Pharmacodynamics.....	12
4.4.3	Pharmacokinetics.....	13
5	SOURCES OF CLINICAL DATA.....	13
5.1	Tables of Studies/Clinical Trials	13
5.2	Review Strategy	15
5.3	Discussion of Individual Studies/Clinical Trials.....	15
6	REVIEW OF EFFICACY	15
	Efficacy Summary.....	15
A.	Study PSY-3007 for the Acute Treatment of Schizophrenia in Adults	15
a.	Rationale for Selection of Studies for Review	15
b.	Study Summaries.....	16
c.	Crosscutting Issues	26
d.	Efficacy Conclusion Regarding Schizophrenia Indication	35

7	REVIEW OF SAFETY	35
	Safety Summary	35
7.1	Methods	36
7.1.1	Studies/Clinical Trials Used to Evaluate Safety	36
7.1.2	Categorization of Adverse Events	36
7.1.3	Pooling of Data Across Studies/Clinical Trials to Estimate and Compare Incidence	36
7.2	Adequacy of Safety Assessments	37
7.2.1	Overall Exposure at Appropriate Doses/Durations and Demographics of Target Populations	37
7.2.2	Explorations for Dose Response	38
7.2.3	Special Animal and/or In Vitro Testing	38
7.2.4	Routine Clinical Testing	38
7.2.5	Metabolic, Clearance, and Interaction Workup	38
7.2.6	Evaluation for Potential Adverse Events for Similar Drugs in Drug Class	38
7.3	Major Safety Results	38
7.3.1	Deaths	38
7.3.2	Nonfatal Serious Adverse Events	39
7.3.3	Dropouts and/or Discontinuations	40
7.3.4	Significant Adverse Events	42
7.3.5	Submission Specific Primary Safety Concerns	43
7.4	Supportive Safety Results	43
7.4.1	Common Adverse Events	43
7.4.2	Laboratory Findings	45
7.4.3	Vital Signs	45
7.4.4	Electrocardiograms (ECGs)	46
7.4.5	Special Safety Studies/Clinical Trials	47
7.4.6	Immunogenicity	47
7.5	Other Safety Explorations	47
7.5.1	Dose Dependency for Adverse Events	47
7.5.2	Time Dependency for Adverse Events	47
7.5.3	Drug-Demographic Interactions	48
7.5.4	Drug-Disease Interactions	49
7.5.5	Drug-Drug Interactions	49
7.5.6	Other Safety Issues with Special Interests	49
7.6	Additional Safety Evaluations	53
7.6.1	Human Carcinogenicity	53
7.6.2	Human Reproduction and Pregnancy Data	53
7.6.3	Pediatrics and Assessment of Effects on Growth	53
7.6.4	Overdose, Drug Abuse Potential, Withdrawal and Rebound	53
7.7	Additional Submissions / Safety Issues	54
8	POSTMARKET EXPERIENCE	54

9 APPENDICES	55
9.1 Literature Review/References	55
9.2 Labeling Recommendations	55
9.3 Advisory Committee Meeting.....	57

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.